$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn

$vrdn Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000159075022000009 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$1.195M	$256.0K	$216.0K
YoY Change	474.52%	-76.51%	-85.11%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.861M	$8.108M	$8.359M
YoY Change	42.44%	24.3%	35.7%
% of Gross Profit
Research & Development	$22.12M	$21.71M	$17.75M
YoY Change	172.37%	72.8%	28.54%
% of Gross Profit
Depreciation & Amortization	$62.00K	$57.00K	$40.00K
YoY Change	106.67%	128.0%	21.21%
% of Gross Profit
Operating Expenses	$30.98M	$29.82M	$26.11M
YoY Change	116.01%	56.22%	30.75%
Operating Profit	-$29.79M	-$29.56M	-$25.89M
YoY Change	110.73%	64.26%	39.83%
Interest Expense	$200.0K	$200.0K	$196.0K
YoY Change	119.78%	488.24%	226.67%
% of Operating Profit
Other Income/Expense, Net	$880.0K	$73.00K	$196.0K
YoY Change	867.03%	114.71%	256.36%
Pretax Income	-$28.91M	-$29.49M	-$25.69M
YoY Change	105.83%	64.17%	39.18%
Income Tax
% Of Pretax Income
Net Earnings	-$28.91M	-$29.49M	-$25.69M
YoY Change	105.83%	64.17%	39.18%
Net Earnings / Revenue	-2418.83%	-11519.92%	-11894.91%
Basic Earnings Per Share	-$0.86	-$1.06	-$0.98
Diluted Earnings Per Share	-$0.86	-$1.06	-$0.98
COMMON SHARES
Basic Shares Outstanding	28.46M shares	27.76M shares	26.13M shares
Diluted Shares Outstanding	33.74M shares	27.76M shares	26.13M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$431.3M	$161.2M	$175.4M
YoY Change	101.73%	47.49%	49.81%
Cash & Equivalents	$344.2M	$31.29M	$30.86M
Short-Term Investments	$87.11M	$129.9M	$144.6M
Other Short-Term Assets	$5.635M	$4.251M	$3.439M
YoY Change	54.43%	3.43%	10.94%
Inventory
Prepaid Expenses
Receivables	$398.0K	$693.0K	$522.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$437.4M	$166.2M	$179.4M
YoY Change	100.68%	43.9%	47.6%
LONG-TERM ASSETS
Property, Plant & Equipment	$825.0K	$749.0K	$691.0K
YoY Change	137.75%	151.34%	366.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.153M	$1.509M	$1.542M
YoY Change	-20.86%	1455.67%	154100.0%
Total Long-Term Assets	$3.225M	$3.663M	$3.776M
YoY Change	-1.23%	33.69%	190.91%
TOTAL ASSETS
Total Short-Term Assets	$437.4M	$166.2M	$179.4M
Total Long-Term Assets	$3.225M	$3.663M	$3.776M
Total Assets	$440.6M	$169.8M	$183.2M
YoY Change	99.17%	43.66%	49.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.15M	$4.061M	$2.538M
YoY Change	225.7%	69.77%	-25.0%
Accrued Expenses	$12.77M	$17.04M	$11.56M
YoY Change	23.78%	20.42%	-9.43%
Deferred Revenue	$288.0K	$288.0K	$288.0K
YoY Change	0.0%	0.0%	0.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$25.21M	$21.39M	$14.39M
YoY Change	75.84%	27.08%	-12.47%
LONG-TERM LIABILITIES
Long-Term Debt	$4.613M	$4.585M	$0.00
YoY Change
Other Long-Term Liabilities	$813.0K	$938.0K	$1.060M
YoY Change	-64.26%	-19.62%	3112.12%
Total Long-Term Liabilities	$813.0K	$938.0K	$1.060M
YoY Change	-64.26%	-19.62%	3112.12%
TOTAL LIABILITIES
Total Short-Term Liabilities	$25.21M	$21.39M	$14.39M
Total Long-Term Liabilities	$813.0K	$938.0K	$1.060M
Total Liabilities	$31.57M	$27.92M	$16.52M
YoY Change	90.04%	44.72%	-1.85%
SHAREHOLDERS EQUITY
Retained Earnings	-$442.4M	-$413.5M	-$384.0M
YoY Change	34.3%	31.14%	29.16%
Common Stock	$402.0K	$285.0K	$272.0K
YoY Change	107.22%	231.4%	277.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$409.0M	$141.9M	$166.6M
YoY Change
Total Liabilities & Shareholders Equity	$440.6M	$169.8M	$183.2M
YoY Change	99.17%	43.66%	49.12%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$28.91M	-$29.49M	-$25.69M
YoY Change	105.83%	64.17%	39.18%
Depreciation, Depletion And Amortization	$62.00K	$57.00K	$40.00K
YoY Change	106.67%	128.0%	21.21%
Cash From Operating Activities	-$20.67M	-$18.09M	-$21.04M
YoY Change	74.05%	23.62%	82.36%
INVESTING ACTIVITIES
Capital Expenditures	-$95.00K	-$292.0K	$179.0K
YoY Change	-48.65%	495.92%	1093.33%
Acquisitions
YoY Change
Other Investing Activities	$42.75M	$14.26M	$9.042M
YoY Change	564.17%	-227.8%	-16.97%
Cash From Investing Activities	$42.65M	$13.96M	$8.863M
YoY Change	582.31%	-224.64%	-18.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	290.9M	4.558M	$738.0K
YoY Change	149.1%	-35.36%	-41.38%
NET CHANGE
Cash From Operating Activities	-20.67M	-18.09M	-$21.04M
Cash From Investing Activities	42.65M	13.96M	$8.863M
Cash From Financing Activities	290.9M	4.558M	$738.0K
Net Change In Cash	312.9M	435.0K	-$11.44M
YoY Change	181.48%	-102.32%	-2032.6%
FREE CASH FLOW
Cash From Operating Activities	-$20.67M	-$18.09M	-$21.04M
Capital Expenditures	-$95.00K	-$292.0K	$179.0K
Free Cash Flow	-$20.57M	-$17.79M	-$21.22M
YoY Change	75.99%	22.04%	83.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36483
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Central Index Key EntityCentralIndexKey	0001590750
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Registrant Name EntityRegistrantName	Viridian Therapeutics, Inc./DE
CY2022Q2	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2022Q2	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-1187261
	dei	Entity Address Address Line1 EntityAddressAddressLine1	221 Crescent Street, Suite 401,
	dei	Entity Address City Or Town EntityAddressCityOrTown	Waltham
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02453
	dei	City Area Code CityAreaCode	617
	dei	Local Phone Number LocalPhoneNumber	272-4600
	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
	dei	Trading Symbol TradingSymbol	VRDN
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28463980	shares
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31293000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42299000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	129914000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	154666000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4251000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2747000	usd
CY2022Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	693000	usd
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	451000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	166151000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	200163000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	749000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	375000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1405000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1680000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1509000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1491000	usd
CY2022Q2	us-gaap	Assets Assets	169814000	usd
CY2021Q4	us-gaap	Assets Assets	203709000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	4061000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2329000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17039000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11018000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	288000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	289000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	21388000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13636000	usd
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	4585000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	0	usd
CY2022Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1005000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1149000	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	938000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1208000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	27916000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	15993000	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28463980	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28463980	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23924004	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23924004	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	285000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	239000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	452696000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	412101000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1077000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-157000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-413484000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-358300000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	141898000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	187716000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	169814000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	203709000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	256000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1090000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	472000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2541000	usd
CY2022Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	21712000	usd
CY2021Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	12565000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	39458000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	26371000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8108000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6523000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16467000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12683000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	29820000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	19088000	usd
	us-gaap	Operating Expenses OperatingExpenses	55925000	usd
	us-gaap	Operating Expenses OperatingExpenses	39054000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-29564000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-17998000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-55453000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-36513000	usd
CY2022Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	227000	usd
CY2021Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	34000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	423000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	89000	usd
CY2022Q2	us-gaap	Interest And Debt Expense InterestAndDebtExpense	154000	usd
CY2021Q2	us-gaap	Interest And Debt Expense InterestAndDebtExpense	0	usd
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	154000	usd
	us-gaap	Interest And Debt Expense InterestAndDebtExpense	0	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	73000	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	34000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	269000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	89000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-29491000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-17964000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-55184000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-36424000	usd
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.06
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.06
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.21
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.21
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.04
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27762257	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27762257	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8106765	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8106765	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26948692	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26948692	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7226447	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7226447	shares
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-29491000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-17964000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-55184000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-36424000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-142000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	9000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-920000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-4000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-142000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	9000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-920000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29633000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17955000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-56104000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-36428000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	187716000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	667000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	71000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4659000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-778000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-25693000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	166642000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4885000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-142000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-29491000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	141898000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	120037000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
CY2021Q1	mgen	Stock Issued During Period Value Warrants Exercised Value StockIssuedDuringPeriodValueWarrantsExercisedValue	940000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	307000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	12000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3175000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-13000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-18460000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	105998000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7052000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3817000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	9000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-17964000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	98912000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-55184000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-36424000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9544000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6992000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	51000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	97000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	58000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-534000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-481000	usd
	mgen	Non Cash Lease Expense NonCashLeaseExpense	44000	usd
	mgen	Non Cash Lease Expense NonCashLeaseExpense	-1200000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-67000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1520000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2156000	usd
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	243000	usd
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	2051000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-144000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	779000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1732000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1732000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1601000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5961000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5683000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-39128000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26170000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	5192000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	67381000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	28489000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	67042000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	471000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	69000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	75000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	22826000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-333000	usd
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	4554000	usd
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8529000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	218000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	671000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	71000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5296000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8311000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11006000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-18192000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42299000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	45897000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31293000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27704000	usd
	us-gaap	Interest Paid Net InterestPaidNet	67000	usd
	us-gaap	Interest Paid Net InterestPaidNet	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	120000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-413500000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	161200000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	162169000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s condensed consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual for clinical trial costs and other outsourced research and development expenses, and the valuation of share-based awards. Although these estimates are based on the Company’s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</span></div>
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The </span></div>Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution.
CY2021Q2	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022Q2	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2021Q2	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2022Q2	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1077000	usd
CY2022Q2	mgen	Operating Lease Annual Base Rent OperatingLeaseAnnualBaseRent	400000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	161092000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	197022000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	6000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	163000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	196865000	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	4000	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P24M
CY2022Q2	mgen	Accrued Outsourcing Clinicaland Preclinical Studies AccruedOutsourcingClinicalandPreclinicalStudies	13197000	usd
CY2021Q4	mgen	Accrued Outsourcing Clinicaland Preclinical Studies AccruedOutsourcingClinicalandPreclinicalStudies	6316000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2577000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3652000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	580000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	520000	usd
CY2022Q2	mgen	Accrued Legal Fees Current AccruedLegalFeesCurrent	79000	usd
CY2021Q4	mgen	Accrued Legal Fees Current AccruedLegalFeesCurrent	80000	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	385000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	140000	usd
CY2022Q2	mgen	Accrued Liabilityof Warrantson Temporary Equity AccruedLiabilityofWarrantsonTemporaryEquity	100000	usd
CY2021Q4	mgen	Accrued Liabilityof Warrantson Temporary Equity AccruedLiabilityofWarrantsonTemporaryEquity	100000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	121000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	210000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17039000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11018000	usd
	us-gaap	Interest Expense InterestExpense	200000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	200000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1600000	usd
	mgen	Lessee Operating Lease Number Of Renewal Terms LesseeOperatingLeaseNumberOfRenewalTerms	3	renewal_term
CY2022Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P3Y
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1600000	usd
CY2021Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.06
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12M
CY2021Q2	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	200000	usd
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	100000	usd
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	100000	usd
CY2020Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.06
CY2022Q2	mgen	Area Of Office Space Expanded AreaOfOfficeSpaceExpanded	2432	sqft
CY2022Q2	mgen	Area Of Office Space Terminated AreaOfOfficeSpaceTerminated	1087	sqft
CY2022Q2	mgen	Area Of Office Space Extension AreaOfOfficeSpaceExtension	3284	sqft
CY2022Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P4Y
CY2022Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P3Y
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	600000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	900000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	100000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	300000	usd
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	100000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	200000	usd
CY2022Q2	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	83000	usd
	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	100000	usd
CY2021Q2	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	34000	usd
	mgen	Operating Leases Operating Expense OperatingLeasesOperatingExpense	68000	usd
CY2022Q2	mgen	Capital Stock Shares Authorized CapitalStockSharesAuthorized	205000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q2	mgen	Common Stock Voteper Share CommonStockVoteperShare	1	vote
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q2	mgen	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Net ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet	420629	shares
CY2021Q4	mgen	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Net ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet	420629	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	15.91
	mgen	Class Of Warrant Or Right Exercised In Period ClassOfWarrantOrRightExercisedInPeriod	0	shares
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3817000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5409700	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	3882163	shares
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4885000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9544000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6992000	usd
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	56900000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y7D
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20275384	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25827559	shares

Files In Submission

Name	View Source	Status
0001590750-22-000009-index-headers.html	Edgar Link	pending
0001590750-22-000009-index.html	Edgar Link	pending
0001590750-22-000009.txt	Edgar Link	pending
0001590750-22-000009-xbrl.zip	Edgar Link	pending
ex102_bi-watchfactoryxviri.htm	Edgar Link	pending
ex10_3amendedandrestated20.htm	Edgar Link	pending
ex311_2022-06.htm	Edgar Link	pending
ex312_2022-06.htm	Edgar Link	pending
ex321_2022-06.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_0.jpg	Edgar Link	pending
image_1.jpg	Edgar Link	pending
image_3.jpg	Edgar Link	pending
image_4.jpg	Edgar Link	pending
image_5.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mgen-20220630.htm	Edgar Link	pending
mgen-20220630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
mgen-20220630_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
mgen-20220630_pre.xml	Edgar Link	unprocessable
mgen-20220630_htm.xml	Edgar Link	completed
mgen-20220630_lab.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
mgen-20220630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn

2022 Q3 Form 10-Q Financial Statement

#000159075022000009 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRDN Viridian Therapeutics, Inc.\DE Stock $vrdn

2022 Q3 Form 10-Q Financial Statement

#000159075022000009 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn